Dr. Reddy's Laboratories Limited (RDY)
NYSE: RDY · Real-Time Price · USD
13.94
+0.07 (0.50%)
Nov 14, 2025, 4:00 PM EST - Market closed
Dr. Reddy's Laboratories Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Dr. Reddy's Laboratories stock has a target of 16.9, which predicts a 21.23% increase from the current stock price of 13.94.
Price Target: $16.9 (+21.23%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Jun 5, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Dr. Reddy's Laboratories is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HSBC | HSBC | Hold → Strong Buy Upgrades $14 → $17 | Hold → Strong Buy | Upgrades | $14 → $17 | +21.23% | Jun 5, 2025 |
| Barclays | Barclays | Buy Maintains $17 → $17 | Buy | Maintains | $17 → $17 | +21.95% | Nov 6, 2024 |
| Barclays | Barclays | Buy Maintains $16 → $17 | Buy | Maintains | $16 → $17 | +24.82% | Jul 30, 2024 |
| Barclays | Barclays | Buy Maintains $16 → $16 | Buy | Maintains | $16 → $16 | +16.21% | May 8, 2024 |
| Barclays | Barclays | Buy Maintains $15 → $16 | Buy | Maintains | $15 → $16 | +14.78% | Jan 29, 2024 |
Financial Forecast
Revenue This Year
346.02B
from 325.54B
Increased by 6.29%
Revenue Next Year
355.03B
from 346.02B
Increased by 2.61%
EPS This Year
63.97
from 67.78
Decreased by -5.62%
EPS Next Year
57.18
from 63.97
Decreased by -10.61%
Financial currency is INR. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 391.3B | 404.3B | |||
| Avg | 346.0B | 355.0B | |||
| Low | 286.1B | 310.7B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 20.2% | 16.9% | |||
| Avg | 6.3% | 2.6% | |||
| Low | -12.1% | -10.2% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 78.23 | 72.66 | |
| Avg | 63.97 | 57.18 | |
| Low | 52.72 | 41.06 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 15.4% | 13.6% | |
| Avg | -5.6% | -10.6% | |
| Low | -22.2% | -35.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.